Selected research
Industry Research
Polypeptide Drug Industry Research Report 2026
Market perspective
The global Polypeptide Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Polypeptide Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Polypeptide Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Polypeptide Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Polypeptide Drug include Takeda, Sanofi, Novartis, Roche, Lilly, Ferring Pharmaceuticals, AstraZeneca, SciClone Pharmaceuticals and Merck Serono, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Polypeptide Drug market in terms of revenue (US$ million) and, where applicable, sales volume (Tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Polypeptide Drug Market by Company
Takeda
Sanofi
Novartis
Roche
Lilly
Ferring Pharmaceuticals
AstraZeneca
SciClone Pharmaceuticals
Merck Serono
Ipsen PHarma Biotech
Asahi Kasei
Polypeptide Drug Segment by Type
Injection
Oral Administration
Transdermal Administration
Lung Administration
Nasal Administration
Polypeptide Drug Segment by Application
Tumor Drug
Digestive System Drugs (Gastrointestinal Type)
Immunity Regulating Medicine (Allergy Infection and Immune)
Urinary System Drug
Bone and Connective Tissue Types (Thyroid hormones Drug)
Gynecologic or Obstetric Drug
Metabolic Drug (Insulin and Other Hypoglycemic Agents)
Polypeptide Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Polypeptide Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Polypeptide Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Polypeptide Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Polypeptide Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Polypeptide Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Polypeptide Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Injection
- Oral Administration
- Transdermal Administration
- Lung Administration
- Nasal Administration
Applications
- Tumor Drug
- Digestive System Drugs (Gastrointestinal Type)
- Immunity Regulating Medicine (Allergy Infection and Immune)
- Urinary System Drug
- Bone and Connective Tissue Types (Thyroid hormones Drug)
- Gynecologic or Obstetric Drug
- Metabolic Drug (Insulin and Other Hypoglycemic Agents)
Companies covered
- Takeda
- Sanofi
- Novartis
- Roche
- Lilly
- Ferring Pharmaceuticals
- AstraZeneca
- SciClone Pharmaceuticals
- Merck Serono
- Ipsen PHarma Biotech
- Asahi Kasei
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Polypeptide Drug Market Size (2021-2032)
- 2.2.2 Global Polypeptide Drug Sales (2021-2032)
- 2.2.3 Global Polypeptide Drug Market Average Price (2021-2032)
- 2.3 Polypeptide Drug by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Injection
- 2.3.3 Oral Administration
- 2.3.4 Transdermal Administration
- 2.3.5 Lung Administration
- 2.3.6 Nasal Administration
- 2.4 Polypeptide Drug by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Tumor Drug
- 2.4.3 Digestive System Drugs (Gastrointestinal Type)
- 2.4.4 Immunity Regulating Medicine (Allergy Infection and Immune)
- 2.4.5 Urinary System Drug
- 2.4.6 Bone and Connective Tissue Types (Thyroid hormones Drug)
- 2.4.7 Gynecologic or Obstetric Drug
- 2.4.8 Metabolic Drug (Insulin and Other Hypoglycemic Agents)
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Polypeptide Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Polypeptide Drug Sales (Tons) of Manufacturers (2021-2026)
- 3.3 Global Polypeptide Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Polypeptide Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Polypeptide Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Polypeptide Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Polypeptide Drug, Product Type & Application
- 3.8 Global Manufacturers of Polypeptide Drug, Established Date
- 3.9 Global Polypeptide Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Takeda
- 4.1.1 Takeda Company Information
- 4.1.2 Takeda Business Overview
- 4.1.3 Takeda Polypeptide Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Takeda Polypeptide Drug Product Portfolio
- 4.1.5 Takeda Recent Developments
- 4.2 Sanofi
- 4.2.1 Sanofi Company Information
- 4.2.2 Sanofi Business Overview
- 4.2.3 Sanofi Polypeptide Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Sanofi Polypeptide Drug Product Portfolio
- 4.2.5 Sanofi Recent Developments
- 4.3 Novartis
- 4.3.1 Novartis Company Information
- 4.3.2 Novartis Business Overview
- 4.3.3 Novartis Polypeptide Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Novartis Polypeptide Drug Product Portfolio
- 4.3.5 Novartis Recent Developments
- 4.4 Roche
- 4.4.1 Roche Company Information
- 4.4.2 Roche Business Overview
- 4.4.3 Roche Polypeptide Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Roche Polypeptide Drug Product Portfolio
- 4.4.5 Roche Recent Developments
- 4.5 Lilly
- 4.5.1 Lilly Company Information
- 4.5.2 Lilly Business Overview
- 4.5.3 Lilly Polypeptide Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Lilly Polypeptide Drug Product Portfolio
- 4.5.5 Lilly Recent Developments
- 4.6 Ferring Pharmaceuticals
- 4.6.1 Ferring Pharmaceuticals Company Information
- 4.6.2 Ferring Pharmaceuticals Business Overview
- 4.6.3 Ferring Pharmaceuticals Polypeptide Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Ferring Pharmaceuticals Polypeptide Drug Product Portfolio
- 4.6.5 Ferring Pharmaceuticals Recent Developments
- 4.7 AstraZeneca
- 4.7.1 AstraZeneca Company Information
- 4.7.2 AstraZeneca Business Overview
- 4.7.3 AstraZeneca Polypeptide Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 AstraZeneca Polypeptide Drug Product Portfolio
- 4.7.5 AstraZeneca Recent Developments
- 4.8 SciClone Pharmaceuticals
- 4.8.1 SciClone Pharmaceuticals Company Information
- 4.8.2 SciClone Pharmaceuticals Business Overview
- 4.8.3 SciClone Pharmaceuticals Polypeptide Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 SciClone Pharmaceuticals Polypeptide Drug Product Portfolio
- 4.8.5 SciClone Pharmaceuticals Recent Developments
- 4.9 Merck Serono
- 4.9.1 Merck Serono Company Information
- 4.9.2 Merck Serono Business Overview
- 4.9.3 Merck Serono Polypeptide Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Merck Serono Polypeptide Drug Product Portfolio
- 4.9.5 Merck Serono Recent Developments
- 4.10 Ipsen PHarma Biotech
- 4.10.1 Ipsen PHarma Biotech Company Information
- 4.10.2 Ipsen PHarma Biotech Business Overview
- 4.10.3 Ipsen PHarma Biotech Polypeptide Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Ipsen PHarma Biotech Polypeptide Drug Product Portfolio
- 4.10.5 Ipsen PHarma Biotech Recent Developments
- 4.11 Asahi Kasei
- 4.11.1 Asahi Kasei Company Information
- 4.11.2 Asahi Kasei Business Overview
- 4.11.3 Asahi Kasei Polypeptide Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Asahi Kasei Polypeptide Drug Product Portfolio
- 4.11.5 Asahi Kasei Recent Developments
5 Global Polypeptide Drug Market Scenario by Region
- 5.1 Global Polypeptide Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Polypeptide Drug Sales by Region: 2021-2032
- 5.2.1 Global Polypeptide Drug Sales by Region: 2021-2026
- 5.2.2 Global Polypeptide Drug Sales by Region: 2027-2032
- 5.3 Global Polypeptide Drug Revenue by Region: 2021-2032
- 5.3.1 Global Polypeptide Drug Revenue by Region: 2021-2026
- 5.3.2 Global Polypeptide Drug Revenue by Region: 2027-2032
- 5.4 North America Polypeptide Drug Market Facts & Figures by Country
- 5.4.1 North America Polypeptide Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Polypeptide Drug Sales by Country (2021-2032)
- 5.4.3 North America Polypeptide Drug Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Polypeptide Drug Market Facts & Figures by Country
- 5.5.1 Europe Polypeptide Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Polypeptide Drug Sales by Country (2021-2032)
- 5.5.3 Europe Polypeptide Drug Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Polypeptide Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Polypeptide Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Polypeptide Drug Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Polypeptide Drug Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Polypeptide Drug Market Facts & Figures by Country
- 5.7.1 South America Polypeptide Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Polypeptide Drug Sales by Country (2021-2032)
- 5.7.3 South America Polypeptide Drug Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Polypeptide Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Polypeptide Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Polypeptide Drug Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Polypeptide Drug Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Polypeptide Drug Sales by Type (2021-2032)
- 6.1.1 Global Polypeptide Drug Sales by Type (2021-2032) & (Tons)
- 6.1.2 Global Polypeptide Drug Sales Market Share by Type (2021-2032)
- 6.2 Global Polypeptide Drug Revenue by Type (2021-2032)
- 6.2.1 Global Polypeptide Drug Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Polypeptide Drug Revenue Market Share by Type (2021-2032)
- 6.3 Global Polypeptide Drug Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Polypeptide Drug Sales by Application (2021-2032)
- 7.1.1 Global Polypeptide Drug Sales by Application (2021-2032) & (Tons)
- 7.1.2 Global Polypeptide Drug Sales Market Share by Application (2021-2032)
- 7.2 Global Polypeptide Drug Revenue by Application (2021-2032)
- 7.2.1 Global Polypeptide Drug Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Polypeptide Drug Revenue Market Share by Application (2021-2032)
- 7.3 Global Polypeptide Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Polypeptide Drug Value Chain Analysis
- 8.1.1 Polypeptide Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Polypeptide Drug Production Mode & Process
- 8.2 Polypeptide Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Polypeptide Drug Distributors
- 8.2.3 Polypeptide Drug Customers
9 Global Polypeptide Drug Analyzing Market Dynamics
- 9.1 Polypeptide Drug Industry Trends
- 9.2 Polypeptide Drug Industry Drivers
- 9.3 Polypeptide Drug Industry Opportunities and Challenges
- 9.4 Polypeptide Drug Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst